PMID- 29255368
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220311
IS  - 1178-7007 (Print)
IS  - 1178-7007 (Electronic)
IS  - 1178-7007 (Linking)
VI  - 10
DP  - 2017
TI  - Effect of different doses of statins on the development of type 2 diabetes 
      mellitus in patients with myocardial infarction.
PG  - 481-489
LID - 10.2147/DMSO.S149463 [doi]
AB  - BACKGROUND: Cardiovascular diseases and type 2 diabetes mellitus (T2DM) may have 
      common developmental mechanisms associated with lipid metabolism disorders. 
      Dyslipidemia and progression of atherosclerosis in people with T2DM are 
      accompanied by an increase in cardiovascular mortality. This study examined the 
      dose-dependent action of atorvastatin on carbohydrate metabolism and adipokine 
      status in patients within 12 months after myocardial infarction (MI). METHODS: A 
      total of 156 male MI patients who had received atorvastatin 20 mg/day (78 
      patients) or 40 mg/day (78 patients) starting from day 1 of onset were enrolled. 
      Glucose, insulin, C-peptide, resistin, adiponectin, and ghrelin levels were 
      measured at baseline, day 12, and months 3 and 12. Patients were monitored for 
      new incidences of T2DM for 12 months after MI. RESULTS: For acute phase MI, 
      patients had moderate insulin resistance, hyperglycemia, and hyper-insulinemia, 
      high leptin and resistin levels, and low ghrelin and adiponectin levels. 
      Atorvastatin 20 mg/day was more effective at correcting the imbalances. Patients 
      taking atorvastatin 40 mg/day (group 2) following MI showed increases in levels 
      of glucose, insulin, and C-peptide and insulin resistance progression after 12 
      months of therapy, as evidenced by increased quantitative insulin sensitivity 
      check index scores and detection of new T2DM cases. CONCLUSION: Atorvastatin 
      improved adipokine profiles and ghrelin levels, with low doses showing more 
      significant effects. Atorvastatin dose prescribed for MI patients should take 
      into account the degree of insulin resistance and adipokine status.
FAU - Gruzdeva, Olga
AU  - Gruzdeva O
AD  - Federal State Budgetary Institution, Research Institute for Complex Issues of 
      Cardiovascular Diseases, Kemerovo, Russia.
FAU - Uchasova, Evgenya
AU  - Uchasova E
AD  - Federal State Budgetary Institution, Research Institute for Complex Issues of 
      Cardiovascular Diseases, Kemerovo, Russia.
FAU - Dyleva, Yulia
AU  - Dyleva Y
AD  - Federal State Budgetary Institution, Research Institute for Complex Issues of 
      Cardiovascular Diseases, Kemerovo, Russia.
FAU - Akbasheva, Olga
AU  - Akbasheva O
AD  - State Budget Educational Institution of Higher Professional Education, Siberian 
      State Medical University, Russian Federation Ministry of Health, Tomsk, Russia.
FAU - Karetnikova, Victoria
AU  - Karetnikova V
AD  - Federal State Budgetary Institution, Research Institute for Complex Issues of 
      Cardiovascular Diseases, Kemerovo, Russia.
FAU - Shilov, Aleksandr
AU  - Shilov A
AD  - Federal State Budgetary Institution, Research Institute for Complex Issues of 
      Cardiovascular Diseases, Kemerovo, Russia.
FAU - Barbarash, Olga
AU  - Barbarash O
AD  - Federal State Budgetary Institution, Research Institute for Complex Issues of 
      Cardiovascular Diseases, Kemerovo, Russia.
LA  - eng
PT  - Journal Article
DEP - 20171205
PL  - New Zealand
TA  - Diabetes Metab Syndr Obes
JT  - Diabetes, metabolic syndrome and obesity : targets and therapy
JID - 101515585
CIN - Diabetes Metab Syndr Obes. 2018 Apr 12;11:131. PMID: 29697702
PMC - PMC5722009
OTO - NOTNLM
OT  - adipokine
OT  - inflammation
OT  - myocardial infarction
OT  - resistin
OT  - statin
COIS- Disclosure The authors report no conflicts of interest in this work.
EDAT- 2017/12/20 06:00
MHDA- 2017/12/20 06:01
PMCR- 2017/12/05
CRDT- 2017/12/20 06:00
PHST- 2017/12/20 06:00 [entrez]
PHST- 2017/12/20 06:00 [pubmed]
PHST- 2017/12/20 06:01 [medline]
PHST- 2017/12/05 00:00 [pmc-release]
AID - dmso-10-481 [pii]
AID - 10.2147/DMSO.S149463 [doi]
PST - epublish
SO  - Diabetes Metab Syndr Obes. 2017 Dec 5;10:481-489. doi: 10.2147/DMSO.S149463. 
      eCollection 2017.